Teva is stubbornly defending its blockbuster multiple sclerosis drug Copaxone, talking up gene expression data and the safety concerns of generic variants. But rival Mylan says it has engaged diligently with the FDA and that, barring administrative hurdles, it may be closer to final approval.
Story Source: The above story is based on materials provided by Pharmamedtechbi
Note: Materials may be edited for content and length
Click here to read original article